Abatacept: first T cell co‐stimulation modulator for severe active RA

Abatacept (Orencia) is licensed for the treatment of severe RA in combination with methotrexate when at least one anti‐TNF agent has failed. Here, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects, and Dr Andrew Ostor comments on its place in RA therapy. Copyright © 2007 Wiley Interface Ltd